A comprehensive view of Gene Therapy & Regenerative Medicine. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Logistic & Supply Chain Market Intelligence Service.
Charles River partners with Singapore's Yong Loo Lin School of Medicine to develop and manufacture plasmid DNA for engineered stem cell cancer therapy; partnership to use Charles River's CDMO expertise in HQ and GMP-compliant plasmid DNA
Published:
March 26, 2024
by Zack's Commentary
|
AGC Biologics to Manufacture First-ever FDA Approved Gene Therapy for Early-onset Metachromatic Leukodystrophy, Orchard Therapeutics’ Lenmeldy™ (atidarsagene autotemcel)
Published:
March 19, 2024
by News Direct
|
FDA Approves First Gene Therapy for Pediatric MLD from Orchard Therapeutics, and AGC Biologics Tapped to Manufacture It
Published:
March 19, 2024
by Biopharm International
|
Charles River Laboratories partners with Navega Therapeutics to produce gene therapy candidate NT-Z001 for Phase 1 clinical trials; the deal leverages Charles River's advisory services and contract development and manufacturing capabilities
Published:
March 15, 2024
by Zack's Commentary
|
Takeda is closing production at its gene therapy plant in Orth, Austria, resulting in nearly 200 job losses; despite attempts to sell the adeno-associated virus gene therapy facility, the Japan-based firm was unable to find a buyer
Published:
March 13, 2024
by FiercePharma
|
Ask us about our Logistic & Supply Chain market view